目的 探討舒血寧注射液聯(lián)合蚓激酶治療腦梗死患者的臨床療效。方法 收集2015年3月—2017年4月來北京市房山區(qū)良鄉(xiāng)醫(yī)院（首都醫(yī)科大學(xué)良鄉(xiāng)教學(xué)醫(yī)院）就診的腦梗死患者86例為研究對(duì)象，隨機(jī)分為對(duì)照組和治療組，每組各43例。對(duì)照組口服蚓激酶腸溶膠囊，60萬單位/次，3次/d，飯前30 min口服。治療組在對(duì)照組治療基礎(chǔ)上靜脈滴注舒血寧注射液，20 mL/次，1次/d。兩組均連續(xù)治療14 d。觀察兩組的臨床療效，比較兩組治療前后神經(jīng)功能缺損（NIHSS）評(píng)分、日常生活活動(dòng)能力（ADL）評(píng)分、血清鐵蛋白（SF）、C反應(yīng)蛋白（CRP）水平的變化情況。結(jié)果 治療后，對(duì)照組和治療組患者的總有效率分別為76.7%、93.0%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組NIHSS評(píng)分、SF、CRP均顯著降低，ADL評(píng)分均顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組NIHSS評(píng)分、SF、CRP低于對(duì)照組，ADL評(píng)分高于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 舒血寧注射液聯(lián)合蚓激酶治療腦梗死具有較好的臨床療效，能改善患者的神經(jīng)功能缺損狀況，明顯提高患者的日常生活活動(dòng)能力，具有一定的臨床推廣應(yīng)用價(jià)值。

objective To explore the clinical curative effect of Shuxuening Injection combined with lumbrokinase in treatment of cerebral infarction. Methods Patients (86 cases) with cerebral infarction in Liangxiang Hospital of Fangshan District in Beijing (Liangxiang Teaching Hospital of Capital Medical University) from March 2015 to April 2017 were randomly divided into control (43 cases) and treatment (43 cases) groups. Patients in the control group were po administered with Lumbrokinase Enteric-coated Capsules, 6×10⁵ U/time, three times daily. Patients in the treatment group were iv administered Shuxuening Injection on the basis of the control group, 20 mL/time, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the changes of NIHSS score, ADL score, and the levels of SF and CRP in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 76.7% and 93.0%, respectively, and there was difference between two groups (P < 0.05). After treatment, NIHSS score, SF, and CRP levels in two groups were decreased, but ADL score was increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, NIHSS score, SF, and CRP levels in the treatment group were higher than those in the control group, but ADL score was lower than that in the control group, and there was difference between two groups (P < 0.05). Conclusion Shuxuening Injection combined with lumbrokinase has clinical curative effect in treatment of cerebral infarction, and can improve the neurological deficit, and can improve daily activities, which has a certain clinical application value.